Ascendis Health's Pharma division has successfully been awarded a R350m state antibiotics tender. The products which will be distributed over a 2 year period, will allow Ascendis to further secure its leading position in the supply of antibiotics to the State.
The tender mainly covers specialist first generation molecules which are first line treatments used by the state to control infections.
Ascendis is set to begin with the distribution activity towards the end of November 2015 in tandem with a national education program regarding antibiotic stewardship. The program mainly aims at healthcare practitioners at government hospitals and clinics. It will reinforce the judicial use of antibiotics to combat resistance.
Dr Karsten Wellner, CEO of Ascendis Health said, We are extremely pleased to have secured this important tender, as it is a clear indication of the success of our integration strategies by unlocking value across the production and supply chain, allowing us to offer a growing range of world class products at competitive pricing.
The tender mainly covers specialist first generation molecules which are first line treatments used by the state to control infections.
Ascendis is set to begin with the distribution activity towards the end of November 2015 in tandem with a national education program regarding antibiotic stewardship. The program mainly aims at healthcare practitioners at government hospitals and clinics. It will reinforce the judicial use of antibiotics to combat resistance.
Dr Karsten Wellner, CEO of Ascendis Health said, We are extremely pleased to have secured this important tender, as it is a clear indication of the success of our integration strategies by unlocking value across the production and supply chain, allowing us to offer a growing range of world class products at competitive pricing.